Jpmorgan Chase & CO Outlook Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.2 - $1.78 $3,945 - $35,110	-19,725 Reduced 16.37%	100,788 $22,000
Q2 2023 Aug 11, 2023	BUY	$1.02 - $1.89 $1,829 - $3,390	1,794 Added 1.51%	120,513 $209,000
Q1 2023 May 18, 2023	BUY	$1.0 - $1.35 $118,474 - $159,939	118,474 Added 48356.73%	118,719 $129,000
Q1 2023 May 11, 2023	SELL	$1.0 - $1.35 $67,052 - $90,520	-67,052 Reduced 99.64%	245 $0
Q4 2022 Feb 13, 2023	BUY	$0.87 - $1.33 $2,234 - $3,415	2,568 Added 3.97%	67,297 $72,000
Q3 2022 Nov 14, 2022	BUY	$1.02 - $1.26 $1,380 - $1,704	1,353 Added 2.13%	64,729 $79,000
Q2 2022 Aug 11, 2022	BUY	$0.91 - $2.01 $9,019 - $19,921	9,911 Added 18.54%	63,376 $65,000
Q1 2022 May 11, 2022	BUY	$1.22 - $2.03 $23,166 - $38,547	18,989 Added 55.08%	53,465 $95,000
Q4 2021 Feb 10, 2022	SELL	$1.27 - $2.23 $14,408 - $25,299	-11,345 Reduced 24.76%	34,476 $47,000
Q3 2021 Nov 12, 2021	BUY	$2.12 - $2.76 $97,140 - $126,465	45,821 New	45,821 $100,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.17B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.